Separately, BMO Capital Markets started coverage on shares of Stealth BioTherapeutics in a research report on Tuesday. They set an “outperform” rating and a $29.00 target price on the stock.
Equities research analysts at Evercore ISI began coverage on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Evercore ISI’s price objective indicates a potential upside of 134.43% from the stock’s current price.
Shares of NASDAQ MITO opened at $14.93 on Tuesday. Stealth BioTherapeutics has a 12-month low of $11.11 and a 12-month high of $20.99.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Further Reading: Short Selling – Explanation For Shorting Stocks